Antimicrobial agents for the treatment of enteric fever chronic carriage: A systematic review

Background Chronic carriage of S. Typhi or S. Paratyphi is an important source of enteric fever transmission. Existing guidance and treatment options for this condition are limited. This systematic review aims to assess the evidence concerning the efficacy of different antimicrobials in treating enteric fever chronic carriage. Methods We searched major bibliographic databases using relevant keywords between 1946 and September 2021. We included all interventional studies that included patients with confirmed enteric fever chronic carriage and deployed an antimicrobial that remains in clinical practice today. Case reports and case series of under 10 patients were excluded. Two reviewers screened abstracts, selected articles for final inclusion and quality-assessed the included studies for risk of bias. Extracted data was analysed, with pooling of data and eradication rates for each antimicrobial calculated. As only one randomised controlled trial was identified, no meta-analysis was performed. Results Of the 593 papers identified by the initial search, a total of eight studies met the inclusion criteria and were included in the systematic review. Evidence was identified for the use of fluoroquinolones and amoxicillin/ampicillin in the treatment for enteric fever chronic carriage. Fluoroquinolones were superior to amoxicillin/ampicillin with 92% of patients achieving eradication after one antimicrobial course compared to 68% (p = 0.02). The quality of included studies was poor, and all were carried out before 1990. Conclusion This review identified fluoroquinolones and amoxicillin/ampicillin as treatment options for enteric fever chronic carriage, with fluoroquinolones the more effective option. However, this evidence pre-dates rises in antimicrobial resistance in enteric fever and therefore the significance of these findings to today’s practice is unclear. Further research is needed to investigate whether these antimicrobials remain appropriate treatment options or whether alternative interventions are more effective.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2021. ; https://doi.org/10.1101/2021.11.09.21266081 doi: medRxiv preprint overall odds ratio of gallbladder cancer in S. Typhi carriers of 4.28 (95% CI: 120 1.84-9.96) (11). 121 122 The identification and treatment of chronic carriers therefore has both a 123 significant public health and arguably individual benefit. There is currently 124 limited evidence or guidance on how these chronic carriers should be treated. increasing across sub-Saharan Africa (16)(17)(18). Multi-drug resistance (MDR), 135 resistance to amoxicillin, co-trimoxazole, chloramphenicol, is also seen in around 136 40% of patients worldwide (16). A current outbreak of extensively-drug-137 resistant (XDR) enteric fever in Pakistan has highlighted the limited 138 antimicrobial treatment options available for acute enteric fever in this setting. 139 The options for antimicrobial treatment of enteric fever chronic carriers in the 140 era of drug-resistance are unknown. 141

142
The aim of this systematic review is to review the existing evidence of efficacy of 143 antimicrobials in treating enteric fever chronic carriage. By doing so we hope to 144 . CC-BY 4.0 International license It is made available under a perpetuity.
is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint ("typhoid" OR "paratyphoid" OR "salmonella typhi" OR "salmonella paratyphi 157 "OR "enteric fever") AND 158 ("chronic carriage" OR "disease carrier "OR "carrier state" OR "typhoid carrier" 159 OR "paratyphoid carrier" AND 160 ("antibiotic" OR "antibacterial" OR "antibacterial treatment" OR "antibiotic 161 treatment" OR "antibacterial agent" OR "antibiotic agent" OR names of individual 162 antibiotics). The full list of search terms is listed in the supplementary 163 information (S1). No language restrictions were included in the initial search. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2021.  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2021. ; https://doi.org/10.1101/2021.11.09.21266081 doi: medRxiv preprint Most of the studies investigated participants for underlying gallstones before 279 enrolment in the study using ultrasound or cholangiography or X-ray. However, 280 in some patients the biliary tract was not well visualised and two studies did not 281 investigate for underlying gallstones prior to enrolment (30,34). These patients 282 were categorised in a third category 'gallstone status unknown'. between the different studies (see Table 1). One study also included separate 291 arms of the study with patients undergoing cholecystectomy and 292 cholecystectomy in combination with ampicillin treatment (26). In this study six 293 of the patients undergoing antimicrobial treatment alone had previously 294 undergone cholecystectomy in the other arm of the study. These were included 295 as they were confirmed to still be chronic carriers 1 year post cholecystectomy 296 and prior to enrolment in the antimicrobial arm. 297 298 Quality assessment 299 Overall methodological quality of included studies was poor (see Table 1). There 300 was only one randomised and blinded study, with the majority of studies 301 designed as pre-and post-studies without a control. 302 . CC-BY 4.0 International license It is made available under a perpetuity.
is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2021. ; https://doi.org/10.1101/2021.11.09.21266081 doi: medRxiv preprint In the RCT study, the outcomes were inconsistently reported with the summary 303 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2021. ; https://doi.org/10.1101/2021.11.09.21266081 doi: medRxiv preprint 1 -One patient was excluded from norfloxacin analysis in Gottuzo paper due poor adherence 340 2 -In Gotuzzo paper 10 placebo patients were re-treated with norfloxacin openly taking the total 341 number of treatment courses given in this paper to 23.

343
In the RCT the norfloxacin group had a higher proportion of S. Typhi eradication 344 than the control group (92% vs 8%, p <0.001). 345 346

Effect of gallstones on eradication 347
Patients in the ciprofloxacin study were not routinely screened for biliary 348 disease before enrolment in the study, however two patients were known to 349 have gallstones. In the norfloxacin study patients underwent oral 350 cholecystogram, IV cholangiography or gallbladder ultrasound before enrolment. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2021. ; https://doi.org/10.1101/2021.11.09.21266081 doi: medRxiv preprint urticarial rash). Of note, three other patients in this study had a haemoglobin 359 drop that were attributed to ciprofloxacin therapy. Norfloxacin was relatively 360 well-tolerated in the other study with only one patient reporting a rash, although 361 these are not further explored in this paper. 362 363

Effect of repeated courses 364
In the norfloxacin study patients initially treated with placebo were then 365 retreated with norfloxacin. This group had a slightly lower eradication 366 proportion of 70%, lowering the overall eradication proportion to 83% per 367 antibiotic course overall. 368 369

Ampicillin/amoxicillin 370
The remaining six studies identified assessed amoxicillin or ampicillin 371 (amox/amp) use. The results of these are summarized in Table 3. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2021. ; https://doi.org/10.1101/2021.11.09.21266081 doi: medRxiv preprint

Phillips
Simon is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2021. ; https://doi.org/10.1101/2021.11.09.21266081 doi: medRxiv preprint 376 377 378 Overall, 101 patients were given a total of 115 courses of amox/amp (either PO 379 or IV). Most of these patients were female and 28% had confirmed gallstones. 380 Only one patient had S. Paratyphi. The dosing regimens were relatively high with 381 the mean daily dose of amoxicillin 4.5g/day but this varied significantly between 382 studies (range 3-5.5g/day). The mean duration of treatment was 37 days but 383 again this was highly variable between regimens (range 15-90 days). 384

385
The overall eradication proportion after a single course of amox/amp was 68% 386 but again, this was highly variable between studies (range 38-100%). 387 388 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

Effect of administration method on eradication 389
The copyright holder for this this version posted November 9, 2021. ; https://doi.org/10.1101/2021.11.09.21266081 doi: medRxiv preprint There was only one study looking at the effect of IV ampicillin on chronic 390 carriage eradication proportion(28). The mean daily dose and total cumulative 391 dose of IV ampicillin used in this study were much lower than those used in the 392 oral studies (3g vs a mean of 4.7g for the oral studies). However, the eradication 393 proportion in this study was notably higher when compared to the oral 394 ampicillin studies (100% vs 60%, p <0.01) with no failures described in the IV 395 arm. 396 397

Effect of dosing regimen and duration on eradication 398
The total daily dose of amox/amp varied between 4 and 5.5g for the studies 399 using oral intervention, with the total drug given over the duration of the course 400 between 112g to 360g. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2021. ; https://doi.org/10.1101/2021.11.09.21266081 doi: medRxiv preprint (total daily dose of 3 grams) was started. This regimen only had a 40% 414 eradication proportion after 28 days, but the numbers were very small. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2021. ; https://doi.org/10.1101/2021.11.09.21266081 doi: medRxiv preprint All studies investigated for prior presence of gallstones except Phillips et al. 439 The eradication proportion was lower in those with gallstones compared to 440 those without gallstones (55% vs 79%, p = 0.039). Those  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2021. ; https://doi.org/10.1101/2021.11.09.21266081 doi: medRxiv preprint Fluoroquinolones have a higher overall eradication proportion than amox/amp 464 (92% vs 68%, p = 0.02). In those with gallstones the eradication proportion 465 remains higher in those taking a Fq compared to those taking amox/amp but this 466 is not significant (82% vs 55%, p = 0.16). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2021. ; https://doi.org/10.1101/2021.11.09.21266081 doi: medRxiv preprint on this subject. Most of these studies were case reports, small case series or did 487 not report on necessary outcome data. 488

489
The findings of this systematic review should be interpreted with caution. 490 Firstly, the overall quality of the included studies was poor, with only one RCT 491 included. The remainder of the studies were case series or pre-and post-studies 492 with no control group and no blinding, which allowed for significant bias. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Prior guidance similarly states that carriers with underlying gallstones are 571 unlikely to be eradicated with antimicrobials alone (12,15). In contrast, this 572 review shows relatively good eradication proportions in those with gallstones, 573 particularly when Fq treatment was used, albeit lower than those without 574 gallstones. Furthermore, many of the identified carriers in this review were not 575 found to have gallstones, despite thorough investigation. It is evident that further 576 work is required to better understand the pathophysiology of chronic carriage to 577 allow the development of targeted interventions. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2021. ; https://doi.org/10.1101/2021.11.09.21266081 doi: medRxiv preprint 587 Side effects of medications were also poorly reported across studies. Some 588 adverse events were linked to the intervention without obvious causality e.g. 589 ciprofloxacin causing haemoglobin drop, when this is not a known common side 590 effect. Furthermore, associations of Fq therapy that were not recognised when 591 these studies took place, for example tendinopathy and aneurysm rupture, may 592 have been under-reported. The recent realisation of potential significant side 593 effects of Fq use has also led to restrictions in their use and they may no longer 594 be suitable to treat patients with chronic carriage, again highlighting the need for 595 alternative treatment strategies (64,65). 596 597 In this review we excluded case reports or case series of less than 10 patients in 598 attempt to reduce bias but in doing so may have excluded studies with additional 599 interventions. Furthermore, the evidence relating to this topic is almost all more 600 than 30 years old and some full-text articles were not able to be accessed, some 601 of which may have otherwise been included in the final review. The strengths of 602 our study include a comprehensive search strategy, the use of two independent 603 reviewers throughout the process and the use of well-defined data extraction 604 and quality assessment tools. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2021. ; https://doi.org/10.1101/2021.11.09.21266081 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint
is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2021. ; https://doi.org/10.1101/2021.11.09.21266081 doi: medRxiv preprint